Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

"Genomics of prostate cancer- implications for managing high risk disease"


Ash TewariAshutosh (Ash) K. Tewari is a world-renowned urologist and prostate cancer specialist. As Director of the Department of Urology at the Icahn School of Medicine at Mount Sinai Hospital in New York, he leads a multidisciplinary team committed to improving prostate cancer treatment, research and education. To date, he has performed over 5,000 robotic radical prostatectomy surgeries. The Tewari Lab is working on unlocking the genomic causes of prostate cancer and translating genomic information to practical physician application through imaging. In 2012, he was awarded the American Urological Association’s Gold Cystoscope Award. This honor is given annually to the urologist who has contributed significantly to the field within 10 years of completing residency. Dr Tewari holds several leadership positions domestically and internationally.

Clinical care
Dr Tewari’s case series is one of the largest in the world and his outcomes are considered the gold standard for this procedure. Dr Tewari’s clinical expertise in prostate cancer includes targeted biopsies, cystoscopies, robotic prostatectomies, as well as the management of active surveillance prostate cancer patients. He has also initiated clinical protocols investigating the utility of focal therapy platforms for the treatment of prostate cancer. Dr Tewari has been consecutively listed in New York Magazine’s Top Doctors issue since 2006.

Dr Tewari’s research approaches the problem of prostate cancer from distinct perspectives.
His outcomes research group is investigating the epidemiological effects of prostate cancer. He is also investigating several novel imaging techniques for identifying prostate cancer imaging biomarkers. And Dr Tewari is working to unlock the genomic causes of prostate cancer.


The lecture will be chaired by Professor Freddie Hamdy, Head of Department at the Nuffield Department of Surgical Sciences. 

All members of the University and NHS clinical staff are welcome.